Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma

• DOI: 10.1016/j.lungcan.2023.107360
• Publication Date: 2023-09-07T15:51:43Z
• Authors: Paul Stockhammer; Hannah Baumeister; Till Ploenes; Francesco Bonella; Dirk Theegarten; Balazs Dome; Christine Pirker; Walter Berger; Luca Hegedüs; Marcell Baranyi; Martin Schuler; Sophie Deshayes; Servet Bölükbas; Clemens Aigner; Christophe Blanquart; Balazs Hegedüs
• Keywords: Pleural disease

Pleural mesothelioma (PM) is a rare disease with dismal outcome. Systemic treatment options include chemotherapy and immunotherapy, but biomarkers for personalization are missing. The only FDA-approved diagnostic biomarker the soluble mesothelin-related protein (SMRP). Krebs von den Lungen-6 (KL-6) human mucin 1 (MUC1) glycoprotein, which has shown prognostic value as in other malignancies. present study investigated whether KL-6 can serve and/or PM.Using fully-automated chemiluminescence enzyme immunoassay (CLEIA) SMRP, pleural effusion samples from 87 consecutive patients PM 25 non-malignant disorders were studied. In addition, SMRP levels determined corresponding patient sera, an independent validation cohort (n = 122). MUC1 mRNA expression, cell line supernatants primary lines vitro.PM had significantly higher than controls (AUC 0.78, p < 0.0001). Among patients, highest those epithelioid or biphasic histologies. There was strong positive correlation between of (p sera similarly associated diagnosis PM, however, to lesser extent 0.71, 0.008). high (≥303 IU/mL) better overall survival (OS) compared low (HR 0.51, 0.004). Congruently, tumor expression prolonged OS 0.35, These findings confirmed cohort.This first demonstrating potential novel liquid-based PM.